3-year update on the ELOQUENT-2 clinical trial of elotuzumab in multiple myeloma
What are the benefits of having different chronic lymphocytic leukemia (CLL) treatment options?
The 20th anniversary of the German CLL Study Group and the importance of collaboration
How can plasma cell leukemia be managed?
Idelalisib plus bendamustine and rituximab improves the outcome of relapsed/refractory CLL